KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortization of GoodwillCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in Working CapitalChange in Working CapitalDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Other Working Capital Changes (2016 - 2026)

Teva Pharmaceutical Industries filings provide 18 years of Other Working Capital Changes readings, the most recent being -$302.0 million for Q1 2026.

  • On a quarterly basis, Other Working Capital Changes fell 2920.0% to -$302.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$1.2 billion, a 310.24% decrease, with the full-year FY2025 number at $81.0 million, down 85.54% from a year prior.
  • Other Working Capital Changes hit -$302.0 million in Q1 2026 for Teva Pharmaceutical Industries, up from -$1.5 billion in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $592.0 million in Q2 2024 to a low of -$1.5 billion in Q4 2025.
  • Median Other Working Capital Changes over the past 5 years was $2.0 million (2024), compared with a mean of -$45.1 million.
  • The widest YoY moves for Other Working Capital Changes: up 27950.0% in 2025, down 3991.89% in 2025.
  • Teva Pharmaceutical Industries' Other Working Capital Changes stood at $179.0 million in 2022, then crashed by 263.13% to -$292.0 million in 2023, then surged by 87.33% to -$37.0 million in 2024, then tumbled by 3991.89% to -$1.5 billion in 2025, then surged by 80.05% to -$302.0 million in 2026.
  • The last three reported values for Other Working Capital Changes were -$302.0 million (Q1 2026), -$1.5 billion (Q4 2025), and $561.0 million (Q3 2025) per Business Quant data.